A Double-Blind, Placebo-Controlled, Safety Tolerability and Pharmacokinetics Study in Parkinson¿s Disease Participants Treated with Carbidopa/Levodopa and NE3107 Phase 2a

Administered By

Awarded By

Contributors

Start/End

  • February 22, 2022 - December 31, 2023